TIDMRSW
RNS Number : 5319A
Renishaw PLC
03 February 2022
Renishaw plc
3 February 2022
Interim report 2022 - for the six months ended 31 December
2021
Highlights
Renishaw, the global provider of manufacturing technologies,
analytical instruments and medical devices, today reports its
half-year results for the six months to 31 December 2021.
6 months 6 months Year ended
to to 30 June
31 December 31 December 2021
2021 2020
Revenue (GBPm) 325.2 255.1 565.6
Adjusted(1) profit before
tax (GBPm) 84.2 43.4 119.7
Adjusted(1) earnings
per share (pence) 97.2 49.2 132.0
Dividend per share (pence) 16.0 14.0 66.0
Statutory profit before
tax (GBPm) 81.5 63.9 139.4
Statutory earnings per
share (pence) 94.2 72.1 153.2
-- Record first-half revenue and adjusted profit before tax.
-- Revenue growth of 27% to GBP325.2m, with:
-- Record level of demand as key market sectors recover and
semiconductor and electronics remain strong; and
-- Strong growth in all regions, continuing the trend seen in 2021 H2.
-- Adjusted(1) profit before tax increased by 94% to GBP84.2m,
with return on revenue increasing to 26% from 17% last year.
-- Statutory profit before tax of GBP81.5m (H1 20/21: GBP63.9m ).
-- Robust balance sheet with net cash and bank deposit balances
of GBP222.0m, compared with GBP215.0m at 30 June 2021, with the
GBP37.8m final dividend for FY20/21 paid in H1.
-- Interim dividend of 16.0p per share.
"We achieved very strong revenue growth in all regions and there
was growth for all product lines within our Manufacturing
technologies segment, most notably for the encoder and gauging
lines. The strong demand for our encoder product lines continues to
be driven by increased investments in industrial automation and the
semiconductor and electronics capital equipment markets, while our
gauging line is benefiting from a recovery in metal cutting
operations and increased investments in shopfloor metrology."
Sir David McMurtry, Executive Chairman.
(1) Note 11, 'Alternative performance measures', defines how
adjusted profit before tax and earnings per share are
calculated.
Overview for the six months ended 31 December 2021
We have continued to deliver on our purpose of making it
possible to create the products, materials and therapies that will
define our world in the decades to come and touch billions of
lives.
Revenue
Revenue for the six months ended 31 December 2021 was GBP325.2m,
an increase of 27% compared with GBP255.1m for the corresponding
period last year. We achieved very strong revenue growth in all
regions and there was growth for all product lines within our
Manufacturing technologies segment, most notably for the encoder
and gauging lines. The strong demand for our encoder product lines
continues to be driven by increased investments in industrial
automation and the semiconductor and electronics capital equipment
markets, while our gauging line is benefiting from a recovery in
metal cutting operations and increased investments in shopfloor
metrology. The notable increase in demand from the Americas and
EMEA that we experienced in the second-half of FY20/21 has
continued, as these economies recovered from the impacts of the
pandemic. The investments that we made in manufacturing resources
in the 2021 calendar year have allowed us to meet the challenges
presented by a record order intake and deliver the strong increase
in first-half revenue and profit.
First half First half Change % Constant
FY21/22 FY20/21 fx(1) change
%
Group revenue GBP325.2m GBP255.1m +27 +30
------------ ------------ --------- --------------
Comprising:
------------ ------------ --------- --------------
APAC GBP160.6m GBP125.9m +28 +32
------------ ------------ --------- --------------
Americas GBP69.1m GBP54.7m +26 +32
------------ ------------ --------- --------------
EMEA GBP95.5m GBP74.5m +28 +27
------------ ------------ --------- --------------
Operating costs
Our gross margin (excluding engineering costs) for this
half-year at 35.5% of revenue is similar to the previous year,
however we have seen an increase in the cost of some purchased
materials and an adverse currency impact, which have been offset by
improved efficiencies resulting from higher production volumes.
The Group headcount has increased during the first half of the
financial year and was 4,975 at the end of December 2021 compared
to 4,664 at the end of June 2021 and 4,324 at the end of December
2020. This increase is primarily due to additional manufacturing
staff to ensure we have sufficient capacity to meet demand,
targeted growth to support product development, and recruitment for
our future talent programmes. Labour costs, excluding bonus
provisions and prior year overseas job retention grant income, were
GBP115.1m in this half-year compared to GBP102.4m last year, with
the average headcount in the first half-year being 4,832 (H1 20/21:
4,371). As part of our ongoing staff development and retention
programmes, which includes ensuring competitive remuneration
packages, we have recently undertaken extensive salary benchmarking
exercises in certain areas of the business, including the UK. This
has led to targeted investments which will result in around GBP5m
of additional annual labour cost going forward.
Certain other operating costs, such as travel and exhibitions,
are higher this half-year compared to last year as some
restrictions relating to the pandemic have been lifted. We have
also experienced an increase in utilities costs, arising from
increasing energy prices and usage. The impact of these increases
will result in higher costs in the second half of the year. No
significant asset impairments have been recognised in this
half-year, or in the previous half-year.
We remain committed to our long-term strategy of developing
innovative and patented products to create strong market positions.
During the first six months of this year, we incurred net
engineering expenditure of GBP37.8m compared with GBP37.2m last
year, which includes our continuing commitment to support existing
products and technologies. We continue to prioritise those
'flagship' projects that either bring faster revenue benefits or
are strategically important to the business. At the EMO Milano
exhibition in October, we launched the REVO(R) ultrasonic probe
(RUP1) which allows the measurement of thickness on components,
such as aircraft landing gear parts and power generation drive
shafts, where access to internal features is challenging.
Profit and tax
Adjusted profit before tax(1) for the first half-year was
GBP84.2m compared with GBP43.4m last year, primarily due to the
revenue growth, giving a return on revenue of 26% (H1 FY20/21:
17%). Statutory profit before tax for the first half-year was
GBP81.5m, compared with GBP63.9m last year, which includes a
GBP2.9m fair value loss on financial instruments not effective for
hedge accounting and not included in adjusted profit before tax.
The gain in the previous half-year relates primarily to proportions
of forward contracts which failed hedge effectiveness testing in
FY19/20, after the global macroeconomic uncertainty resulted in
reductions to the highly probable forecasts of the hedged item. No
further contracts have been designated as ineffective in the six
months to 31 December 2021.
The income tax expense in the Consolidated income statement has
been estimated at a rate of 15.9% (H1 20/21: 18.0%) and is based on
management's best estimate of the full year effective tax rates by
geographical unit applied to half-year profits. The reduced
effective tax rate mainly arises from a forecast increase in the UK
Patent Box benefit from nil in the prior year.
Adjusted earnings per share were 97.2p, compared with 49.2p last
year. Statutory earnings per share were 94.2p, compared with 72.1p
last year.
Manufacturing technologies
Revenue for our manufacturing technologies segment, which
comprises our Industrial Metrology, Position Measurement and
Additive Manufacturing businesses, was GBP308.7m for the first six
months, compared with GBP236.9m last year(2) . Adjusted operating
profit was GBP81.3m, compared with GBP41.1m for the comparable
period last year(2) . We have seen growth in demand for all our
Manufacturing technologies product lines, notably in our gauging
product line, and our magnetic and optical encoder product lines.
The latter has seen strong growth due to significant global
investments in the semiconductor and electronics capital equipment
market, driven by an increase in both consumer and commercial
demand for electronic products, the growth in electric vehicles
which contain more sensors than conventional vehicles, and the
desire for more nations to become self-sufficient in semiconductor
manufacturing. Magnetic encoders manufactured by our associate
company, RLS, also experienced strong growth due to increased
demand for industrial automation products. We also experienced good
growth in demand for our machine tool and co-ordinate measuring
machine product lines, where our global customer base and strong
portfolio of products, including recent introductions, have allowed
us to benefit from a recovery in investments in metal cutting
machinery and the need
to measure the outputs from those processes.
The supply chain challenges that we experienced in FY20/21
continue, especially due to the global shortage of electronic
components. However, these risks are mitigated by our extensive
in-house manufacturing operations, our proactive inventory
management, continual assessment of alternative components, and the
loyalty of our customer base.
Analytical instruments and medical devices
Revenue from our analytical instruments and medical devices
segment for the first six months was GBP16.5m, compared with
GBP18.3m last year(2) . The adjusted operating profit was GBP1.6m
in the first half of this year compared with a GBP2.3m for the
comparable period last year(2) . Despite a good order book, our
spectroscopy line saw a small reduction in revenue due to delays
shipping product to China where some customers are experiencing
long lead-times in obtaining duty exemption certificates. Excluding
China, revenue has increased year-on-year.
Balance sheet
Capital expenditure for this half-year was GBP12.2m (H1 20/21:
GBP4.8m) and was primarily on plant and equipment to support our
manufacturing processes and IT infrastructure, and the completion
of our new distribution facility in South Korea.
Inventory balances have increased by GBP22.3m since 30 June
2021, in line with increases in global demand and reflecting
planned increases in certain component safety stock levels to
mitigate global supply shortages. Trade receivables have decreased
by GBP2.8m in the same period reflecting a reduction in debtor
days.
Net cash and bank deposit balances at 31 December 2021 were
GBP222.0m, compared with GBP215.0m at 30 June 2021, primarily
reflecting the cash generated from operating profit, offset by the
working capital movement, capital expenditure, tax payments and the
final dividend payment for FY20/21.
Dividend
The Board has approved an interim dividend of 16.0 pence net per
share (2021: 14.0p) which will be paid on 11 April 2022 to
shareholders on the register on 11 March 2022.
Principal risks and uncertainties
The Board has considered the risks and uncertainties which could
have a material effect on the Group's performance and position.
While there is continuing uncertainty regarding the impact of
COVID-19, as well as global macroeconomic conditions, supply chain
challenges and trade tensions, the overall impact and likelihood of
our principal risks is not considered to have changed
significantly. This conclusion also reflects the mitigation
undertaken by the Group in response to these risks. The principal
risks and uncertainties set out on pages 34 to 43 of the 2021
Annual Report therefore remain relevant.
COVID-19 update
Our priorities continue to be the health and welfare of our
employees, their families and the wider communities in which we
operate, and to maintain high service levels to our global customer
base. Our response and mitigation committee continues to meet at
least twice weekly to review any developments caused by the
pandemic and to take any necessary mitigating actions. We have a
wide-range of robust COVID-secure working practices in place to
protect against the spread of the virus and, within the UK, where
we have higher numbers of employees, we have continued self-testing
for all employees who are working on-site, including daily testing
introduced during the recent Omicron wave of infections. All our
manufacturing facilities around the world are operating as normal,
and we have maintained supply to customers. Many of our
non-manufacturing employees have worked remotely throughout the
pandemic, and while this has generally been a positive experience
in terms of productivity, we recognise the benefits of in-person
collaboration. We have therefore agreed a hybrid working policy,
initially in the UK. The pandemic has brought forward many digital
initiatives, including the expansion of the use of digital
collaborative tools for customer support, and the use of marketing
automation, virtual exhibitions and webinars to ensure a supply of
high-quality sales opportunities.
Brexit
To mitigate against the impacts of the UK leaving the EU, we
have taken actions in recent years including establishing a
warehouse in Ireland, expanding our existing warehouse in Germany,
and increasing the inventory of certain finished goods and
components at sites within the EU and the UK. Although there have
been some delays at the UK borders for shipments into the EU and
for imports from the EU and other regions, including shipments from
our manufacturing facility in India, the measures that we have
taken have minimised the impact on customer service.
Sustainability
From 30 June 2015 to 30 June 2021, we reduced our greenhouse gas
emissions (scopes 1, 2 and measured scope 3) by 39% and by the end
of FY 20/21 80% of our global electricity was from renewable
sources, of which 11% was self-generated. However, like most
organisations there is much more that we must do to meet the
challenges of climate change. At the end of November, we committed
to a science-based Net Zero emissions target by no later than 2050,
with an ambition to bring this date forward once we have a better
understanding of currently unmeasured scope 3 emissions. We are
also currently in the process of agreeing a Net Zero target for
scope 1 and 2 emissions. Our targets will be validated and
monitored by the internationally respected SBTi (Science Based
Target initiative) and as part of this commitment we will also
start to report against the relevant UN Sustainable Development
Goals in this year's Annual Report.
The drive to Net Zero represents many opportunities for our
business as our products positively contribute to our customers own
sustainability ambitions by reducing energy consumption and
minimising waste.
Directors and employees
The Directors would like to thank our employees for their
continuing resilience, skill and dedication throughout the
pandemic, which has ensured continuous supply and support to our
customers, the introduction of innovative new products, the
progression of key projects that will underpin the future success
of our business, and the support for each other and our local
communities. They have truly demonstrated our core values of
innovation, inspiration, integrity and involvement.
On 31 December 2021, Carol Chesney, stepped down from the Board
as a Non-executive Director, Chair of the Audit Committee and a
member of the Remuneration and Nomination Committees. She was
appointed in 2012 and made a considerable contribution to the Board
and Renishaw, and we would like to thank her and wish her well for
the future. Juliette Stacey was appointed to the Board on 1 January
2022 as a Non-executive Director and Chair of the Audit Committee
and has also joined the Nomination and Remuneration Committees.
Juliette is currently Senior Independent Director at Fuller, Smith
& Turner P.L.C. where she is Chair of its Audit Committee and a
member of its Nomination and Remuneration committees. She is also a
Non-executive Director of Sanderson Design Group plc where she is
Chair of its Audit Committee and a member of its Remuneration and
Nomination Committees. Juliette previously held roles as Group
Finance Director and later as Group Chief Executive at Mabey
Holdings Ltd. She brings extensive experience, with her strong
finance and leadership background and will be a valuable addition
to the Company's resources at board level and particularly as Chair
of the Audit Committee.
Outlook
The Board continues to be confident in our long-term prospects
and ability to deliver on our purpose, due to our strong financial
position, the high quality of our people, our innovative product
pipeline, extensive global sales and marketing presence, and
relevance to high-value manufacturing.
We currently have a record order book, and we expect demand from
the semiconductor and electronics sectors to remain strong and that
the recoveries in the machine tool market and co-ordinate measuring
machine market will continue. At this stage, we expect full year
revenue to be in the range of GBP650m to GBP690m. Adjusted profit
before tax is expected to be in the range of GBP157m to GBP181m
.
Sir David McMurtry Will Lee Allen Roberts
Executive Chairman Chief Executive Group Finance
Director
3 February 2022
(1) Note 11, 'Alternative performance measures', defines how
revenue at constant exchange rates, adjusted profit before tax,
operating profit and earnings per share are calculated.
(2) Results relating to sales of additive manufacturing machines
to medical and dental customers are no longer recognised in the
Analytical instruments and medical devices (previously Healthcare)
operating segment. Comparative figures have been reclassified
accordingly, see note 2.
Consolidated income statement
Unaudited Unaudited Audited
6 months 6 months Year ended
to to 30 June
31 December 31 December 2021
Notes 2021 2020 GBP'000
GBP'000 GBP'000
Revenue 2 325,176 255,123 565,559
Cost of sales 3 (153,293) (128,043) (269,852)
Gross profit 171,883 127,080 295,707
Distribution costs (55,830) (54,250) (110,087)
Administrative expenses (33,560) (29,436) (69,257)
(Losses)/gains from the fair value
of financial instruments 10 (2,313) 20,526 21,978
Operating profit 80,180 63,920 138,341
Financial income 4 445 3,629 3,406
Financial expenses 4 (658) (3,641) (3,991)
Share of profits from associates and
joint ventures 1,515 39 1,683
Profit before tax 81,482 63,947 139,439
Income tax expense 5 (12,949) (11,487) (27,980)
Profit for the period 68,533 52,460 111,459
---------------------------------------- -------- ------------- ------------- --------------
Profit attributable to:
Equity shareholders of the parent
company 68,533 52,460 111,459
Non-controlling interest - - -
---------------------------------------- -------- ------------- ------------- --------------
Profit for the period 68,533 52,460 111,459
---------------------------------------- -------- ------------- ------------- --------------
Pence Pence Pence
Dividend per share arising in respect
of the period 7 16.0 14.0 66.0
---------------------------------------- -------- ------------- ------------- --------------
Earnings per share (basic and diluted) 6 94.2 72.1 153.2
---------------------------------------- -------- ------------- ------------- --------------
Consolidated statement of comprehensive income and expense
Unaudited Unaudited Audited
6 months 6 months Year ended
to to 30 June
31 December 31 December 2021
2021 2020 GBP'000
GBP'000 GBP'000
Profit for the period 68,533 52,460 111,459
------------------------------------------------ ------------- ------------- ------------
Other items recognised directly in equity:
Items that will not be reclassified to
the Consolidated income statement:
Current tax on contributions to defined
benefit pension schemes 827 - 1,653
Deferred tax on contributions to defined
benefit pension schemes (827) - (1,653)
Remeasurement of defined benefit pension
scheme liabilities (806) 101 33,285
Deferred tax on remeasurement of defined
benefit pension scheme liabilities 73 (171) (6,052)
Total for items that will not be reclassified (733) (70) 27,233
------------------------------------------------ ------------- ------------- ------------
Items that may be reclassified to the
Consolidated income statement:
Exchange differences in translation of
overseas operations 434 (8,148) (14,752)
Exchange differences in translation of
overseas joint venture (229) (217) (728)
Current tax on translation of net investments
in foreign operations (245) 1,157 735
Deferred tax on translation of net investments
in foreign operations - - 735
Effective portion of changes in fair
value of cash flow hedges, net of recycling (3,256) 40,712 51,590
Deferred tax on effective portion of
changes in fair value of cash flow hedges 607 (7,736) (9,790)
Total for items that may be reclassified (2,689) 25,768 27,790
------------------------------------------------ ------------- ------------- ------------
Total other comprehensive income and
expense, net of tax (3,422) 25,698 55,023
------------------------------------------------ ------------- ------------- ------------
Total comprehensive income and expense
for the period 65,111 78,158 166,482
------------------------------------------------ ------------- ------------- ------------
Attributable to:
Equity shareholders of the parent company 65,111 78,158 166,482
Non-controlling interest - - -
Total comprehensive income and expense
for the period 65,111 78,158 166,482
------------------------------------------------ ------------- ------------- ------------
Consolidated balance sheet
Unaudited Unaudited Audited
At 31 December At 31 December At 30
2021 2020 June
Notes GBP'000 GBP'000 2021
GBP'000
Assets
Property, plant and equipment 8 248,098 257,668 246,242
Intangible assets 9 44,917 43,125 43,795
Right-of-use-assets 11,973 13,489 12,429
Investments in associates and joint
ventures 17,920 16,426 16,634
Long-term loans to associates and - 2,056 -
joint ventures
Finance lease receivables 6,814 5,292 6,241
Deferred tax assets 21,150 25,799 21,292
Derivatives 10 6,836 9,653 12,484
----------------------------------------- -------- ---------------- ---------------- ---------
Total non-current assets 357,708 373,508 359,117
----------------------------------------- -------- ---------------- ---------------- ---------
Current assets
Inventories 135,895 98,152 113,563
Trade receivables 10 111,864 95,582 114,661
Finance lease receivables 1,524 1,731 1,763
Contract assets 757 432 332
Short-term loans to associates
and joint ventures 616 781 598
Current tax 3,279 5,131 1,600
Other receivables 27,174 20,684 30,021
Derivatives 10 9,839 3,192 9,639
Pension scheme cash escrow account 10,580 10,575 10,578
Bank deposits 160,000 80,000 120,000
Cash and cash equivalents 62,038 106,619 95,008
Total current assets 523,566 422,879 497,763
----------------------------------------- -------- ---------------- ---------------- ---------
Current liabilities
Trade payables 27,954 18,441 24,715
Contract liabilities 5,707 6,235 6,120
Current tax 6,700 3,881 4,680
Provisions 6,342 6,279 6,259
Derivatives 10 3,877 7,771 5,594
Lease liabilities 3,644 4,150 3,904
Borrowings 972 3,628 992
Other payables 47,732 40,974 51,716
----------------------------------------- -------- ---------------- ---------------- ---------
Total current liabilities 102,928 91,359 103,980
----------------------------------------- -------- ---------------- ---------------- ---------
Net current assets 420,638 331,520 393,783
----------------------------------------- -------- ---------------- ---------------- ---------
Non-current liabilities
Borrowings 5,919 7,562 6,457
Lease liabilities 8,672 9,569 8,658
Employee benefits 20,229 60,895 23,698
Deferred tax liabilities 12,029 499 10,402
Derivatives 10 1,598 1,394 355
Total non-current liabilities 48,447 79,919 49,570
----------------------------------------- -------- ---------------- ---------------- ---------
Total assets less total liabilities 729,899 625,109 703,330
----------------------------------------- -------- ---------------- ---------------- ---------
Equity
Share capital 14,558 14,558 14,558
Share premium 42 42 42
Own shares held (750) (404) (404)
Currency translation reserve 3,679 10,521 3,719
Cash flow hedging reserve 8,696 2,521 11,345
Retained earnings 704,553 598,490 674,603
Other reserve (302) (42) 44
----------------------------------------- -------- ---------------- ---------------- ---------
Equity attributable to the shareholders
of the parent company 730,476 625,686 703,907
Non-controlling interest (577) (577) (577)
----------------------------------------- -------- ---------------- ---------------- ---------
Total equity 729,899 625,109 703,330
----------------------------------------- -------- ---------------- ---------------- ---------
Consolidated statement of changes in equity
Unaudited Own Currency Cash Non-
Share Share shares translation flow Retained Other controlling
capital premium held reserve hedging earnings reserve interest Total
GBP'000 GBP'000 GBP'000 GBP'000 reserve GBP'000 GBP'000 GBP'000 GBP'000
GBP'000
Balance at 1
July 2020 14,558 42 (404) 17,729 (30,455) 546,100 (129) (577) 546,864
Profit for the
period - - - - - 52,460 - - 52,460
Other
comprehensive
income
and expense
(net of tax)
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Remeasurement
of defined
benefit
pension
liabilities - - - - - (70) - - (70)
Foreign
exchange
translation
differences - - - (6,991) - - - - (6,991)
Relating to
associates
and joint
ventures - - - (217) - - - - (217)
Changes in
fair value
of cash flow
hedges - - - - 32,976 - - - 32,976
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Total other
comprehensive
income and
expense - - - (7,208) 32,976 (70) - - 25,698
Total
comprehensive
income
and expense - - - (7,208) 32,976 52,390 - - 78,158
Transactions
with owners
recorded in
equity
Share-based
payments
charge - - - - - - 87 - 87
Balance at 31
December
2020 14,558 42 (404) 10,521 2,521 598,490 (42) (577) 625,109
Profit for the
period - - - - - 58,999 - - 58,999
Other
comprehensive
income
and expense
(net of tax)
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Remeasurement
of defined
benefit
pension
liabilities - - - - - 27,303 - - 27,303
Foreign
exchange
translation
differences - - - (6,291) - - - - (6,291)
Relating to
associates
and joint
ventures - - - (511) - - - - (511)
Changes in
fair value
of cash flow
hedges - - - - 8,824 - - - 8,824
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Total other
comprehensive
income and
expense - - - (6,802) 8,824 27,303 - - 29,325
Total
comprehensive
income
and expense - - - (6,802) 8,824 86,302 - - 88,324
Transactions
with owners
recorded in
equity
Share-based
payments
charge - - - - - - 86 - 86
Dividends paid - - - - - (10,189) - - (10,189)
Balance at 30
June 2021 14,558 42 (404) 3,719 11,345 674,603 44 (577) 703,330
Profit for the
period - - - - - 68,533 - - 68,533
Other
comprehensive
income
and expense
(net of tax)
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Remeasurement
of defined
benefit
pension
liabilities - - - - - (733) - - (733)
Foreign
exchange
translation
differences - - - 189 - - - - 189
Relating to
associates
and joint
ventures - - - (229) - - - - (229)
Changes in
fair value
of cash flow
hedges - - - - (2,649) - - - (2,649)
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Total other
comprehensive
income and
expense - - - (40) (2,649) (733) - - (3,422)
Total
comprehensive
income
and expense - - - (40) (2,649) 67,800 - - 65,111
Transactions
with owners
recorded in
equity
Share-based
payments net
credit - - - - - - (346) - (346)
Distribution
of own shares - - 404 - - - - - 404
Purchase of
own shares - - (750) - - - - (750)
Dividends paid - - - - - (37,850) - - (37,850)
Balance at 31
December
2021 14,558 42 (750) 3,679 8,696 704,553 (302) (577) 729,899
--------------- --------- --------- -------- ------------ --------- ---------- --------- ------------ ---------
Consolidated statement of cash flow
Unaudited Unaudited Audited
6 months 6 months Year ended
to to 30 June
31 December 31 December 2021
2021 2020 GBP'000
GBP'000 GBP'000
Cash flows from operating activities
Profit for the period 68,533 52,460 111,459
---------------------------------------------------- ------------- ------------- ------------
Adjustments for:
Depreciation of property, plant and equipment
and right-of-use assets 11,729 11,392 28,780
(Profit)/loss on sale of property, plant
and equipment 17 (8) 31
Amortisation of development costs 4,035 4,577 9,019
Impairment of development costs 185 - 1,092
Amortisation of other intangibles 396 735 1,205
Share of profits from associates and joint
ventures (1,515) (39) (1,683)
Impairment of investment in associate - - 1,674
Impairment of long-term loan to associate - - 2,633
Remeasurement of defined benefit pension
scheme liabilities from GMP equalisation - 82 78
Financial income (445) (3,629) (3,406)
Financial expenses 658 3,641 3,991
Losses/(gains) from the fair value of financial
instruments 2,936 (20,537) (22,995)
Share based payment expense 59 87 173
Tax expense 12,949 11,487 27,980
31,004 7,788 48,572
---------------------------------------------------- ------------- ------------- ------------
Decrease/(increase) in inventories (22,332) 7,345 (8,066)
Decrease/(increase) in trade and other receivables 5,375 6,678 (25,703)
(Decrease)/increase in trade and other payables (1,075) 9,481 27,216
(Decrease)/increase in provisions 83 688 668
(17,949) 24,192 (5,885)
---------------------------------------------------- ------------- ------------- ------------
Defined benefit pension contributions (4,431) (4,436) (8,866)
Income taxes paid (10,366) (4,627) (9,991)
Cash flows from operating activities 66,791 75,377 135,289
---------------------------------------------------- ------------- ------------- ------------
Investing activities
Purchase of property, plant and equipment (12,199) (4,825) (10,873)
Sale of property, plant and equipment 363 2,474 33
Development costs capitalised (4,820) (5,074) (9,844)
Purchase of other intangibles (784) (810) (3,000)
Increase in bank deposits (40,000) (70,000) (110,000)
Interest received 261 359 625
Purchase of additional shareholding in joint
venture - - (749)
Cash flows from investing activities (57,179) (77,876) (133,808)
---------------------------------------------------- ------------- ------------- ------------
Financing activities
Increase in borrowings - 636 636
Repayment of borrowings (471) (550) (3,477)
Interest paid (324) (13) (386)
Repayment of principal portion of lease
liabilities (1,741) (2,604) (4,815)
Purchase of own shares (750) - -
Dividends paid (37,845) - (10,189)
Cash flows from financing activities (41,131) (2,531) (18,231)
---------------------------------------------------- ------------- ------------- ------------
Net (decrease)/increase in cash and cash
equivalents (31,519) (5,030) (16,750)
Cash and cash equivalents at the beginning
of the period 95,008 110,386 110,386
Effect of exchange rate fluctuations on
cash held (1,451) 1,263 1,372
---------------------------------------------------- ------------- ------------- ------------
Cash and cash equivalents at the end of
the period 62,038 106,619 95,008
---------------------------------------------------- ------------- ------------- ------------
Notes
1. Basis of preparation
The Interim report, which includes the condensed consolidated
financial statements for the six months ended 31 December 2021, was
approved by the Directors on 3 February 2022.
The condensed consolidated financial statements for the six
months ended 31 December 2021 were prepared in accordance with
International Accounting Standard 34 'Interim Financial Reporting'
(IAS 34) as issued by the International Accounting Standards Board
and as adopted by the UK, and apply the same accounting policies,
presentation and methods of calculation as were applied in the
preparation of the Group's consolidated financial statements for
the year ended 30 June 2021, except for income taxes which are
accrued using the forecast tax rate for the financial year, and
except for the adoption of new accounting standards.
The condensed consolidated financial statements included in this
Report have not been audited and do not constitute the Group's
statutory accounts as defined in section 434 of the Companies Act
2006. The information relating to the year ended 30 June 2021 is an
extract from the Group's published Annual Report for that year,
which has been delivered to the Registrar of Companies, and on
which the auditor's report was unqualified and did not contain any
emphasis of matter or statements under section 498(2) or 498(3) of
the Companies Act 2006.
For the year to 30 June 2022 the annual financial statements
will be prepared in accordance with IFRS as adopted by the UK
Endorsement Board. This change in basis of preparation is required
by UK company law as a result of the UK's exit from the EU on 31
January 2020 and the end of the transition period on 31 December
2020. This change does not constitute a change in accounting policy
but rather a change in accounting policy which is required to
ground the use of IFRS in company law. There is no impact on
recognition, measurement or disclosure between the two frameworks
in the period reported.
Going concern
The Directors have prepared the unaudited interim financial
information on a going concern basis. In considering the going
concern basis, the Directors have considered the above-mentioned
principal risks and uncertainties, as well as the Group's current
trading performance and updated cashflow forecasts.
In the 2021 Annual Report we disclosed details of a 'base'
scenario as well as five 'severe but plausible' scenarios which
were used in the Director's going concern assessment, and viability
statement, as at October 2021. With strong trading performance in
the first half of the year and a record order book, both of our
operating segments are expected to outperform the 'base' scenario
forecasts for the year to 30 June 2022, and performance in
subsequent periods is also expected to outperform the 'base'
scenario. The Directors have continued to monitor the 'severe but
plausible' scenarios, noting no change from the risks identified as
at 30 June 2021, concluding that the Group will have positive cash
balances in all scenarios throughout the going concern period. The
Directors have also considered the financial resources available to
the Group, with net current assets of GBP420.6m at 31 December 2021
(compared to GBP393.8m at 30 June 2021), including GBP222.0m net
cash and bank deposits at 31 December 2021, an increase from
GBP215.0m at 30 June 2021.
Having made appropriate enquiries, the Directors are satisfied
that, at the time of approving the unaudited condensed consolidated
financial statements, it is appropriate to continue to adopt a
going concern basis of accounting.
2. Segmental information
The Group manages its business in two segments, comprising
Manufacturing technologies and Analytical instruments and medical
devices. Within the operating segments, there are multiple product
offerings with similar economic characteristics, similar production
processes and similar customer bases. The results of these segments
are regularly reviewed by the Board to allocate resources and to
assess their performance. More details of the Group's products and
services are given in the Strategic Report of the 2021 Annual
Report.
In normal trading conditions, whilst future revenue is difficult
to predict given that the Group's outstanding order book is
typically less than three months' worth of revenue value, larger
consumer electronics orders in the APAC region within the
manufacturing technologies segment typically fall in the first or
last quarter of the financial year. In addition, the Group
typically experiences lower demand in August and December, and so
revenue and operating profits are typically lower in the first half
of the year. This information is provided to allow for a better
understanding of the results, and management do not believe that
the business is 'highly seasonal' in accordance with IAS 34.
Manufacturing Analytical Total
technologies instruments
and medical
6 months to 31 December 2021 devices
GBP'000 GBP'000 GBP'000
Revenue 308,707 16,469 325,176
Depreciation, amortisation and impairment 15,508 837 16,345
Operating profit before gains from
fair value of financial instruments 80,938 1,555 82,493
Share of profits from associates and
joint ventures 1,515 - 1,515
Net financial expense - - (213)
Gains from the fair value of financial
instruments - - (2,313)
Profit before tax - - 81,482
------------------------------------------- --------------- ------------- --------
6 months to 31 December 2020 (1)
Revenue 236,873 18,250 255,123
Depreciation, amortisation and impairment 14,579 945 15,524
Operating profit before gains from
fair value of financial instruments 41,078 2,316 43,394
Share of profits from associates and
joint ventures 39 - 39
Net financial expense - - (12)
Gains from the fair value of financial
instruments - - 20,526
Profit before tax - - 63,947
------------------------------------------- --------------- ------------- --------
Year ended 30 June 2021 (1)
Revenue 530,445 35,114 565,559
Depreciation, amortisation and impairment 37,909 2,187 40,096
Operating profit before losses from
fair value of financial instruments 111,978 4,385 116,363
Share of profits from associates and
joint ventures 1,683 - 1,683
Net financial expense - - (585)
Gains from the fair value of financial
instruments - - 21,978
Profit before tax - - 139,439
------------------------------------------- --------------- ------------- --------
(1) In previous years, we reported the results of additive
manufacturing machines marketed and sold to medical and dental
customers within Analytical instruments and medical devices
(formerly Healthcare), reflecting how we managed this business. The
management of this now sits within the Additive Manufacturing
product line, with a similar customer base and risk profile to this
product line, with results and operational matters reported to the
Executive Committee and Chief Operating Decision Maker accordingly.
We now therefore report the medical and dental results within
Manufacturing technologies rather than Analytical instruments and
medical devices. Comparative figures have been reclassified
accordingly. For the 6 months to 31 December 2020, revenue of
GBP1,232,000, depreciation and amortisation of GBP695,000, and
operating loss before gains from fair value of financial
instruments of GBP131,000 have been reclassified from Analytical
instruments and medical devices to Manufacturing technologies.
Amounts of GBP4,254,000, GBP993,000 and GBP1,480,000 (profit)
respectively have also been reclassified in the year ended 30 June
2021.
There is no allocation of assets and liabilities to operating
segments. Depreciation is included within certain other overhead
expenditure which is allocated to segments on the basis of the
level of activity.
The following table shows the disaggregation of Group revenue by
category:
6 months to 6 months to Year ended
31 December 31 December 30 June
2021 2020 2021
GBP'000 GBP'000 GBP'000
Goods, capital equipment
and installation 299,077 229,828 513,675
Aftermarket services 26,099 25,295 51,884
Total Group revenue 325,176 255,123 565,559
-------------------------- ------------- ------------- -----------
Aftermarket services include repairs, maintenance and servicing,
programming, training, extended warranties, and software licences
and maintenance.
The following table shows the analysis of revenue by
geographical market:
6 months to 6 months to Year ended
31 December 31 December 30 June
2021 2020 2021
GBP'000 GBP'000 GBP'000
APAC 160,562 125,924 274,765
-------------------------- ------------- ------------- -----------
UK (country of domicile) 15,485 10,864 26,923
EMEA, excluding UK 80,007 63,644 142,219
-------------------------- ------------- ------------- -----------
EMEA 95,492 74,508 169,142
Americas 69,122 54,691 121,652
Total Group revenue 325,176 255,123 565,559
-------------------------- ------------- ------------- -----------
Revenue in the above table has been allocated to regions based
on the geographical location of the customer. Countries with
individually material revenue figures in the context of the Group
were:
6 months to 6 months to Year ended
31 December 31 December 30 June
2021 2020 2021
GBP'000 GBP'000 GBP'000
China 80,700 69,488 141,690
USA 60,324 46,891 103,850
Japan 32,066 24,200 51,523
Germany 27,600 23,038 51,095
There was no revenue from transactions with a single external
customer amounting to 10% or more of the Group's total revenue.
3. Cost of sales
6 months to 6 months Year ended
31 December to 30 June
2021 31 December 2021
GBP'000 2020 GBP'000
GBP'000
Production costs 115,477 90,807 197,805
-------------------------------------- ------------- ------------- -----------
Research and development expenditure 27,944 29,290 58,618
Other engineering expenditure 12,644 10,512 18,019
-------------------------------------- ------------- ------------- -----------
Gross engineering expenditure 40,588 39,802 76,637
-------------------------------------- ------------- ------------- -----------
Development expenditure capitalised
(net of amortisation) (785) (497) (825)
Development expenditure impaired 185 - 1,092
Research and development tax
credit (2,172) (2,070) (4,857)
-------------------------------------- ------------- ------------- -----------
Total engineering costs 37,816 37,235 72,047
Total cost of sales 153,293 128,043 269,852
-------------------------------------- ------------- ------------- -----------
4. Financial income and expenses
6 months 6 months Year ended
to to 30 June
31 December 31 December 2021
2021 2020 GBP'000
GBP'000 GBP'000
Financial income
------------------------------------------ ------------- ------------- -----------
Fair value gains from one-month
forward currency contracts - 3,263 2,781
Currency gains 184 - -
Bank interest receivable 261 366 625
------------------------------------------ ------------- ------------- -----------
Total financial income 445 3,629 3,406
------------------------------------------ ------------- ------------- -----------
Financial expenses
------------------------------------------ ------------- ------------- -----------
Interest on pension schemes' liabilities 156 454 876
Currency losses - 2,720 2,660
Fair value losses from one-month 178 - -
forward currency contracts
Lease interest 236 417 335
Interest payable on borrowings 30 30 69
Other interest payable 58 20 51
Total financial expenses 658 3,641 3,991
------------------------------------------ ------------- ------------- -----------
Currency losses relate to revaluations of foreign
currency-denominated balances using latest reporting currency
exchange rates. Certain intragroup balances are classified as 'net
investments in foreign operations', such that revaluations from
currency movements on designated balances accumulate in the
Currency translation reserve in Equity. Rolling one-month forward
currency contracts are used to offset currency movements on
remaining intragroup balances, with fair value gains and losses
being recognised in financial income or expenses.
5. Taxation
The income tax expense in the Consolidated income statement has
been estimated at a rate of 15.9% (December 2020: 18.0%), based on
management's best estimate of the full year effective tax rates by
geographical unit applied to half-year profits. The reduced
effective tax rate mainly arises from a forecast increase in the UK
Patent Box benefit.
6. Earnings per share
The earnings per share for the six months ended 31 December 2021
is calculated on earnings of GBP68,533,000 (December 2020:
GBP52,460,000) and on 72,774,147 shares (December 2020: 72,778,904
shares), being the number of shares in issue during the period.
This excludes 14,396 shares (December 2020: 9,639 shares) held by
the Renishaw Employee Benefit Trust.
7. Dividends
Dividends paid during the period 6 months to 6 months Year ended
were: 31 December to 30 June
2021 31 December 2021
GBP'000 2020 GBP'000
GBP'000
2021 final dividend paid of 52.0p 37,850 - -
per share (2020: nil)
Interim dividend paid of 14.0p
per share (2021: nil) - - 10,189
Total dividends paid during the
period 37,850 - 10,189
----------------------------------- ------------- ------------- -----------
All shareholders on the register on 11 March 2022 will be paid
an interim dividend of 16.0p net per share on 11 April 2022,
resulting in a dividend payable of GBP11,646,167.
8. Property, plant and equipment
Freehold Plant and Motor Assets in Total
land and equipment vehicles the
buildings course of
construction
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Cost
At 1 July 2021 216,783 242,432 7,421 7,109 473,745
Additions 2,647 2,367 1,258 5,927 12,199
Transfers 39 1,395 - (1,434) -
Disposals - (1,057) (827) - (1,884)
Currency adjustment (126) (83) (12) - (221)
At 31 December 2021 219,343 245,054 7,840 11,602 483,839
----------------------- ----------- ------------ ----------- -------------- --------
Depreciation
At 1 July 2021 38,530 182,557 6,416 - 227,503
Charge for the period 1,756 7,702 290 - 9,748
Released on disposals - (700) (804) - (1,504)
Currency adjustment 11 (14) (3) - (6)
At 31 December 2021 40,297 189,545 5,899 - 235,741
----------------------- ----------- ------------ ----------- -------------- --------
Net book value
At 31 December 2021 179,046 55,509 1,941 11,602 248,098
----------------------- ----------- ------------ ----------- -------------- --------
At 30 June 2021 178,253 59,875 1,005 7,109 246,242
----------------------- ----------- ------------ ----------- -------------- --------
Additions to assets in the course of construction of
GBP5,927,000 (December 2020: GBP3,040,000) comprise GBP1,095,000
(December 2020: GBP251,000) for freehold land and buildings and
GBP4,832,000 (December 2020: GBP2,789,000) for plant and equipment.
At the end of the period, assets in the course of construction, not
yet transferred, of GBP11,602,000 (December 2020: GBP6,663,000)
comprise GBP4,308,000 (December 2020: GBP2,804,000) for freehold
land and buildings and GBP7,294,000 (December 2020: GBP3,859,000)
for plant and equipment.
9. Intangible assets
Goodwill Other intangible Internally Software Total
on consolidation assets generated licences
development and intellectual
costs property
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Cost
At 1 July 2021 19,533 15,783 177,291 24,962 237,569
Additions - - 4,820 784 5,604
Currency adjustment 147 (6) - (14) 127
At 31 December 2021 19,680 15,777 182,111 25,732 243,300
----------------------- ------------------- ----------------- ------------- ------------------ --------
Amortisation
At 1 July 2021 9,028 13,254 151,807 19,685 193,774
Charge for the period - 128 4,035 268 4,431
Impairment - - 185 - 185
Currency adjustment - 6 - (13) (7)
At 31 December 2021 9,028 13,388 156,027 19,940 198,383
----------------------- ------------------- ----------------- ------------- ------------------ --------
Net book value
At 31 December 2021 10,652 2,389 26,084 5,792 44,917
----------------------- ------------------- ----------------- ------------- ------------------ --------
At 30 June 2021 10,505 2,529 25,484 5,277 43,795
----------------------- ------------------- ----------------- ------------- ------------------ --------
As detailed in the 2021 Annual Report, the key assumption in
determining the value-in-use of intangible assets are sales
forecasts. Latest sales forecasts, and other factors which may
impact the business plans, for relevant cash generating units have
been reviewed for indicators of impairment at 31 December 2021. As
a result, total impairments of GBP185,000 have been recognised in
the six months to 31 December 2021 (December 2020: GBPnil).
10. Financial instruments
There is no significant difference between the fair value of
financial assets and financial liabilities and their book value in
the Consolidated balance sheet. All financial assets and
liabilities are held at amortised cost, apart from the forward
exchange contracts which are held at fair value, with changes going
through the Consolidated income statement unless subject to hedge
accounting. The fair values of the forward exchange contracts have
been calculated by a third-party expert, discounting estimated
future cash flows on the basis of market expectations of future
exchange rates, representing level 2 in the IFRS 13 fair value
hierarchy. There were no transfers between levels during any period
disclosed.
Credit risk
The Group carries a credit risk relating to non-payment of trade
receivables by its customers and establishes an allowance for
impairment in respect of trade receivables where recoverability is
considered doubtful. In the six months to 31 December 2021, the
Group has not experienced a deterioration in debtor repayments nor
in the assumptions used in calculating allowances for expected
credit losses. At 31 December 2021, total expected credit losses
amounted to GBP3,544,000, being 3.2% of gross trade receivables,
compared with GBP3,826,000 at 30 June 2021, being 3.2% of gross
trade receivables.
Liquidity risk
The Group's approach to managing liquidity is to ensure, as far
as possible, that it will always have sufficient liquidity to meet
its liabilities when due, and the Group continues to use monthly
cash flow forecasts on a rolling 12-month basis to monitor cash
requirements. With net cash and bank deposits at 31 December 2021
totalling GBP222,038,000, an increase of GBP7,030,000 from 30 June
2021, and bank deposits of maximum six-month maturity, the Group's
liquidity has improved in the six months to 31 December 2021.
Market risk
At 31 December 2021 the total nominal value of USD, EUR and JPY
forward contracts held for cash flow hedging purposes was
GBP516,547,000. At 31 December 2021 the remaining nominal value of
USD, EUR and JPY forward contracts ineffective for cash flow
hedging and yet to mature amounted to GBP109,199,000, with no
additional forward contracts becoming ineffective for hedge
accounting purposes in the six months to 31 December 2021. On an
ongoing basis, a 10% depreciation of GBP against USD, EUR and JPY
would result in a GBP12,133,000 gain being recognised in the
Consolidated Income Statement, while a 10% appreciation would
result in a GBP9,927,000 loss. Fair value gains and losses relating
to this have been excluded from adjusted profit measures, see note
11 for further detail.
11. Alternative performance measures
In accordance with Renishaw's Alternative Performance Measures
(APMs) policy and ESMA Guidelines on Alternative Performance
Measures (2015), APMs are defined as - Revenue at constant exchange
rates, Adjusted profit before tax, Adjusted earnings per share and
Adjusted operating profit.
Revenue at constant exchange rates is defined as revenue
recalculated using the same rates as were applicable to the
previous year and excluding forward contract gains and losses.
Revenue at constant exchange rates 6 months 6 months
to 31 December to 31
2021 December
2020
GBP'000 GBP'000
Statutory revenue as reported 325,176 255,123
Adjustment for forward contract losses (391) 1,375
Adjustment to restate at previous year 9,404 -
exchange rates
Revenue at constant exchange rates 334,189 256,498
------------------------------------------ ---------------- ----------
Year-on-year revenue growth at constant 30% -
exchange rates
------------------------------------------ ---------------- ----------
Adjusted profit before tax, Adjusted earnings per share and
Adjusted operating profit are defined as the profit before tax,
earnings per share and operating profit after excluding third-party
costs relating to the formal sale process ('FSP') concluded in July
2021 and gains and losses in fair value from forward currency
contracts which did not qualify for hedge accounting and which have
yet to mature.
From FY16/17, the gains and losses from the fair value of
financial instruments not effective for cash flow hedging have been
excluded from statutory profit before tax, statutory earnings per
share and statutory operating profit in arriving at Adjusted profit
before tax, Adjusted earnings per share and Adjusted operating
profit, to reflect the Board's intent that the instruments would
provide effective hedges. This is classified as 'Fair value
(gains)/losses on financial instruments not eligible for hedge
accounting (i)' in the following reconciliations. The amounts shown
as reported in revenue represent the amount by which revenue would
change had all the derivatives qualified as eligible for hedge
accounting. Gains and losses which recycle through the Consolidated
income statement as a result of contracts deemed ineffective during
FY19/20 are also excluded from adjusted profit measures, on the
basis that all forward contacts are still expected to be effective
hedges for Group revenue, while the potentially high volatility in
fair value gains and losses relating to these contracts will
otherwise cause confusion for users of the financial statements
wishing to understand the underlying trading performance of the
Group. This is classified as 'Fair value (gains)/losses on
financial instruments not eligible for hedge accounting (ii)' in
the following reconciliations.
The Board considers these alternative performance measures to be
more relevant and reliable in evaluating the Group's
performance.
Adjusted profit before tax 6 months 6 months Year ended
to 31 December to 31 December 30 June
2021 2020 2021
GBP'000 GBP'000 GBP'000
Statutory profit before tax 81,482 63,947 139,439
Third-party FSP costs (200) - 3,222
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (i)
- reported in revenue 2,621 (11) 1,882
- reported in (gains)/losses from the fair
value of financial instruments - derivatives (1,138) 2,763 846
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (ii)
- reported in revenue (1,998) - (2,899)
- reported in (gains)/losses from the fair
value of financial instruments - derivatives 3,451 (23,289) (22,824)
Adjusted profit before tax 84,218 43,410 119,666
---------------------------------------------------- ---------------- ---------------- -----------
Adjusted earnings per share 6 months 6 months Year ended
to 31 to 31 30 June
December December 2021
2021 2020
pence pence pence
Statutory earnings per share 94.2 72.1 153.2
Third-party FSP costs (0.2) - 4.4
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (i)
- reported in revenue 2.9 0.0 2.1
- reported in (gains)/losses from the fair
value of financial instruments - derivatives (1.3) 3.1 0.9
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (ii)
- reported in revenue (2.2) - (3.2)
- reported in (gains)/losses from the fair
value of financial instruments - derivatives 3.8 (25.9) (25.4)
Adjusted earnings per share 97.2 49.3 132.0
---------------------------------------------------- ---------- ---------- -----------
Adjusted operating profit 6 months 6 months Year ended
to 31 December to 30 June
2021 31 December 2021
2020
GBP'000 GBP'000 GBP'000
Statutory operating profit 80,180 63,921 138,341
Third-party FSP costs (200) - 3,222
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (i)
- reported in revenue 2,621 (11) 1,882
- reported in (gains)/losses from the fair
value of financial instruments - derivatives (1,138) 2,763 846
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (ii)
- reported in revenue (1,998) - (2,899)
- reported in (gains)/losses from the fair
value of financial instruments - derivatives 3,451 (23,289) (22,824)
Adjusted operating profit 82,916 43,384 118,568
---------------------------------------------------- ---------------- ------------- -----------
Adjustments to segmental operating profit:
Manufacturing technologies 6 months 6 months Year ended
to 31 December to 30 June
2021 31 December 2021(2)
2020(2)
GBP'000 GBP'000 GBP'000
Operating profit before gain/loss from fair
value of financial instruments 80,938 41,078 111,978
Third-party FSP costs (196) - 3,061
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (i)
- reported in revenue 2,572 (12) 1,797
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (ii)
- reported in revenue (1,960) - (2,734)
Adjusted manufacturing technologies operating
profit 81,354 41,066 114,102
---------------------------------------------------- ---------------- ------------- -----------
Analytical instruments and medical devices 6 months 6 months Year ended
to 31 to 31 30 June
December December 2021(2)
2021 2020(2)
GBP'000 GBP'000 GBP'000
Operating loss before gain/loss from fair
value of financial instruments - derivatives 1,555 2,316 4,385
Third-party FSP costs (4) - 161
Fair value (gains)/losses on financial instruments
not eligible for hedge accounting (i)
- reported in revenue 49 1 86
Fair value gains on financial instruments
not eligible for hedge accounting (ii)
- reported in revenue (38) - (166)
Adjusted analytical instruments and medical
devices operating profit 1,562 2,317 4,466
---------------------------------------------------- ---------- ---------- -----------
(2) Results relating to sales of additive manufacturing machines
to medical and dental customers are no longer recognised in the
Analytical instruments and medical devices (previously Healthcare)
operating segment. Comparative figures have been reclassified
accordingly, see note 2.
12. Related party transactions and events subsequent to the end of the reporting period
Transactions between the Company and its subsidiaries, which are
related parties, have been eliminated on consolidation and are not
disclosed in this note. Full details of the Group's other related
party relationships, transactions and balances are given in the
Group's Annual Report for the year ended 30 June 2021. No related
party transactions have taken place in the first six months of the
financial year that have materially affected the financial position
or the performance of the Group during that period.
In January 2022 an agreement was reached between Renishaw plc
and Meggitt plc for the sale of Renishaw's 33.33% shareholding in
HiETA Technologies Limited to Meggitt plc. This has resulted in a
net gain on disposal of GBP0.5m, to be recognised in the
Manufacturing technologies operating segment in the second half of
the financial year.
13. Responsibility statement
The condensed set of financial statements is the responsibility
of, and has been approved by, the Directors. We confirm that to the
best of our knowledge:
- As required by DTR 4.2 of the Disclosure Rules and
Transparency Rules, the condensed set of financial statements,
which has been prepared in accordance with the applicable set of
accounting standards, gives a true and fair view of the assets,
liabilities, financial position and profit or loss of the Company
and the undertakings included in the consolidation as a whole. The
Interim report has been prepared in accordance with IAS 34,
'Interim Financial Reporting', as issued by the International
Accounting Standards Board and as adopted by the UK.
- The Interim report includes a fair review of the information required by:
(a) DTR 4.2.7 of the Disclosure Rules and Transparency Rules,
being an indication of important events that have occurred during
the first six months of the financial year and their impact on the
condensed set of financial statements; and a description of the
principal risks and uncertainties for the remaining six months of
the year; and
(b) DTR 4.2.8 of the Disclosure Rules and Transparency Rules,
being related party transactions that have taken place in the first
six months of the current financial year and that have materially
affected the financial position or performance of the entity during
that period; and any changes in the related party transactions
described in the last Annual Report that could do so.
On behalf of the Board
Allen Roberts FCA
Group Finance Director
3 February 2022
Financial calendar
2022 interim dividend record 11 March 2022
date
2022 interim dividend payment 11 April 2022
date
Trading statement 10 May 2022
Investor day (provisional) 10 May 2022
Announcement of 2022 full September 2022
year results
Publication of 2022 Annual September 2022
Report
Annual General Meeting October 2022
Registered office:
Renishaw plc
New Mills
Wotton-under-Edge
Gloucestershire
GL12 8JR
UK
Registered
number: 01106260
Telephone: +44 1453 524524
Email: uk@renishaw.com
Website: www.renishaw.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IR UPUPPPUPPGBP
(END) Dow Jones Newswires
February 03, 2022 01:59 ET (06:59 GMT)
Renishaw (LSE:RSW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Renishaw (LSE:RSW)
Historical Stock Chart
From Jul 2023 to Jul 2024